Tonix Pharmaceuticals Holding Corp (NAS:TNXP)
$ 12.04 -0.26 (-2.07%) Market Cap: 206.58 Mil Enterprise Value: 31.62 Mil PE Ratio: 0 PB Ratio: 0.90 GF Score: 39/100

Tonix Pharmaceuticals Holding Corp at RBC Capital Markets Global Healthcare Conference Transcript

May 19, 2026 / 05:35 PM GMT
Release Date Price: $13.71 (-3.86%)


Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

TNXP.OQ - Tonix Pharmaceuticals Holding Corp
Tonix Pharmaceuticals Holding Corp at RBC Capital Markets Global Healthcare Conference
May 19, 2026 / 05:35PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
And today we have Seth Luderman, co-founder, CEO, and Chairman of Tonix Pharmaceuticals.

Let me just start by saying this company accomplished something that is pretty amazing.

First company in 15 years to get a drug approved for fibromyalgia. So I think it's really impressive and I'll start there and then I'll get to a couple of questions.

You just reported $3.7 million in Tonmaya sales, and that was based on 5,400 prescriptions. As we sit here in mid-May, do you see Q2 trends accelerating, or where do we stand, especially given Medicare coverage, GPOs, those sorts of things?

----------------------------------------------------------------
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot